Lipid Nanoparticles-Based Therapy in Liver Metastasis Management: From Tumor Cell-Directed Strategy to Liver Microenvironment-Directed Strategy

References

• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564. doi:10.1126/science.1203543
   PubMed Web of Science ®Google Scholar
• Budczies J, von Winterfeld M, Klauschen F, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6(1):570–583. doi:10.18632/oncotarget.2677
   PubMedGoogle Scholar
• Liu C, Wang T, Yang J, et al. Distant metastasis pattern and prognostic prediction model of colorectal cancer patients based on big data mining. Front Oncol. 2022;12:878805. doi:10.3389/fonc.2022.878805
   PubMedGoogle Scholar
• Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:647684. doi:10.1155/2012/647684
   PubMedGoogle Scholar
• Kulkarni R, Kabir I, Hodson J, et al. Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: a systematic review and meta-analysis. Annals Hepato Biliary Pancreatic Surg. 2022;26(1):31–39. doi:10.14701/ahbps.21-101
   PubMedGoogle Scholar
• Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810. doi:10.1186/1471-2407-14-810
   PubMed Web of Science ®Google Scholar
• Chibani H, El Bairi K, Al Jarroudi O, Afqir S. Bevacizumab in metastatic colorectal cancer in a real-life setting - toxicity profile, survival outcomes, and impact of tumor sidedness. Contemp Oncol. 2022;26(1):32–39. doi:10.5114/wo.2022.114678
   Google Scholar
• Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. Cancer Med. 2020;9(1):361–373. doi:10.1002/cam4.2673
   PubMed Web of Science ®Google Scholar
• Ren Y, Dai C, Zheng H, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7(33):53245–53253. doi:10.18632/oncotarget.10644
   PubMedGoogle Scholar
• Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med. 2020;45(12):935–942. doi:10.1097/rlu.0000000000003307
   PubMed Web of Science ®Google Scholar
• Annala M, Fu S, Bacon JVW, et al. Cabazitaxel versus Abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, Phase II trial. Ann Oncol. 2021;32(7):896–905. doi:10.1016/j.annonc.2021.03.205
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals Oncol. 2021;32(8):994–1004. doi:10.1016/j.annonc.2021.05.801
   PubMed Web of Science ®Google Scholar
• Heesterman BL, van der Poel HG, Schoots IG, Mehra N, Aben KKH. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. BJU Int. 2022;130(2):217–225. doi:10.1111/bju.15632
   PubMed Web of Science ®Google Scholar
• de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–448. doi:10.1097/SLA.0b013e3181b4539b
   PubMed Web of Science ®Google Scholar
• D’Angelica M, Kornprat P, Gonen M, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18(4):1096–1103. doi:10.1245/s10434-010-1409-1
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, Phase 3 trial. Lancet Oncol. 2013;14(12):1208–1215. doi:10.1016/s1470-2045(13)70447-9
   PubMed Web of Science ®Google Scholar
• Cloyd JM, Mizuno T, Kawaguchi Y, et al. Comprehensive complication index validates improved outcomes over time despite increased complexity in 3707 consecutive hepatectomies. Ann Surg. 2020;271(4):724–731. doi:10.1097/sla.0000000000003043
   PubMed Web of Science ®Google Scholar
• Gonsalves CF, Adamo RD, Eschelman DJ. Locoregional therapies for the treatment of uveal melanoma hepatic metastases. Semin Intervent Radiol. 2020;37(5):508–517. doi:10.1055/s-0040-1720948
   PubMedGoogle Scholar
• Rovers KP, Bakkers C, Nienhuijs SW, et al. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. JAMA Surg. 2021;156(8):710–720. doi:10.1001/jamasurg.2021.1642
   PubMed Web of Science ®Google Scholar
• Riesco-Martinez MC, Modrego A, Espinosa-Olarte P, La Salvia A, Garcia-Carbonero R. Perioperative chemotherapy for liver metastasis of colorectal cancer: lessons learned and future perspectives. Curr Treat Options Oncol. 2022;23(9):1320–1337. doi:10.1007/s11864-022-01008-5
   PubMed Web of Science ®Google Scholar
• Bridgewater JA, Pugh SA, Maishman T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398–411. doi:10.1016/s1470-2045(19)30798-3
   PubMed Web of Science ®Google Scholar
• Moosavian SA, Bianconi V, Pirro M, Sahebkar A. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Semin Cancer Biol. 2021;69:337–348. doi:10.1016/j.semcancer.2019.09.025
   PubMed Web of Science ®Google Scholar
• Tsilimigras DI, Brodt P, Clavien PA, et al. Liver metastases. Nature Rev Dis Primers. 2021;7(1):27. doi:10.1038/s41572-021-00261-6
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13(12):527–537. doi:10.1016/s0167-7799(00)89017-4
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572–577. doi:10.1038/s41586-021-03653-6
   PubMed Web of Science ®Google Scholar
• Wu J. The Enhanced Permeability and Retention (EPR) effect: the significance of the concept and methods to enhance its application. J Personal Med. 2021;11(8):771. doi:10.3390/jpm11080771
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil® — the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134. doi:10.1016/j.jconrel.2012.03.020
   PubMed Web of Science ®Google Scholar
• Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999;86(1):72–78. doi:10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987–992.
   PubMed Web of Science ®Google Scholar
• Laufman LR, Spiridonidis CH, Jones JJ, Rhodes V, Rossi K, Wallace K. Phase I study of Doxil and vinorelbine in patients with advanced malignancies. Cancer Invest. 2004;22(3):344–352. doi:10.1081/cnv-200034893
   PubMed Web of Science ®Google Scholar
• Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3(4):406–417. doi:10.1158/2159-8290.Cd-12-0429
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi:10.1056/NEJMoa1716153
   PubMed Web of Science ®Google Scholar
• Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084–1087. doi:10.1038/s41565-019-0591-y
   PubMed Web of Science ®Google Scholar
• NCCN guidelines hepatobiliary cancers (Version 2.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed October 1, 2022.
   Google Scholar
• NCCN guidelines colon cancers (Version 1.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed October 1, 2022.
   Google Scholar
• Kalra AV, Kim J, Klinz SG, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74(23):7003–7013. doi:10.1158/0008-5472.Can-14-0572
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–557. doi:10.1016/s0140-6736(15)00986-1
   PubMed Web of Science ®Google Scholar
• Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101(10):1658–1663. doi:10.1038/sj.bjc.6605374
   PubMed Web of Science ®Google Scholar
• NCCN guidelines pancreatic adenocarcinoma (Version 1.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed October 1, 2022.
   Google Scholar
• Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004;3(1):11–12. doi:10.1038/nrd1287
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–444. doi:10.1002/cncr.27732
   PubMed Web of Science ®Google Scholar
• Gogineni VR, Maddirela DR, Park W, et al. Localized and triggered release of oxaliplatin for the treatment of colorectal liver metastasis. J Cancer. 2020;11(23):6982–6991. doi:10.7150/jca.48528
   PubMed Web of Science ®Google Scholar
• NCCN guidelines breast cancer (Version 4.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed October 1, 2022.
   Google Scholar
• Lin Y, He X, Zhou D, Li L, Sun J, Jiang X. Co-delivery of doxorubicin and itraconazole by Pluronic® P123 coated liposomes to enhance the anticancer effect in breast cancers. RSC Adv. 2018;8(42):23768–23779. doi:10.1039/c8ra03787f
   PubMed Web of Science ®Google Scholar
• Chang YJ, Hsu WH, Chang CH, Lan KL, Ting G, Lee TW. Combined therapeutic efficacy of (188) Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells. Mol Clin Oncol. 2014;2(3):380–384. doi:10.3892/mco.2014.246
   PubMedGoogle Scholar
• Simberg D, Weisman S, Talmon Y, Faerman A, Shoshani T, Barenholz Y. The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem. 2003;278(41):39858–39865. doi:10.1074/jbc.M302232200
   PubMed Web of Science ®Google Scholar
• Hattori Y, Arai S, Okamoto R, Hamada M, Kawano K, Yonemochi E. Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver. Int J Pharm. 2014;476(1–2):289–298. doi:10.1016/j.ijpharm.2014.09.059
   PubMedGoogle Scholar
• Wang Y, Tang Y, Zhao XM, et al. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy. Acta biomaterialia. 2022;153:481–493. doi:10.1016/j.actbio.2022.09.046
   PubMed Web of Science ®Google Scholar
• Ryschich E, Huszty G, Knaebel HP, Hartel M, Büchler MW, Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer. 2004;40(9):1418–1422. doi:10.1016/j.ejca.2004.01.036
   PubMed Web of Science ®Google Scholar
• Karabicici M, Alptekin S, Fırtına Karagonlar Z, Erdal E. Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM-/CD133- nonstem cell population in hepatocellular carcinoma cell line, HuH-7. Mol Oncol. 2021;15(8):2185–2202. doi:10.1002/1878-0261.12916
   PubMed Web of Science ®Google Scholar
• Özdemir A, Şimay Demir YD, Yeşilyurt ZE, Ark M. Chapter four - senescent cells and SASP in cancer microenvironment: new approaches in cancer therapy. In: Donev R, editor. Advances in Protein Chemistry and Structural Biology. Academic Press; 2023:115–158.
   Google Scholar
• Camp ER, Wang C, Little EC, et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013;20(4):222–228. doi:10.1038/cgt.2013.9
   PubMed Web of Science ®Google Scholar
• Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323–1334. doi:10.1016/j.cell.2006.12.007
   PubMed Web of Science ®Google Scholar
• Ichihara H, Hino M, Umebayashi M, Matsumoto Y, Ueoka R. Intravenous injection of hybrid liposomes suppresses the liver metastases in xenograft mouse models of colorectal cancer in vivo. Eur J Med Chem. 2012;57:143–148. doi:10.1016/j.ejmech.2012.08.040
   PubMed Web of Science ®Google Scholar
• Liao R, Zhang XD, Li GZ, Qin KL, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2020;11(4):747–759. doi:10.21037/jgo-20-59
   PubMed Web of Science ®Google Scholar
• Wei-Ze L, Wen-Xia H, Ning Z, et al. A novel embolic microspheres with micro nano binary progressive structure for transarterial chemoembolization applications. Eur J Pharma Sci. 2020;153:105496. doi:10.1016/j.ejps.2020.105496
   PubMed Web of Science ®Google Scholar
• Pohlen U, Buhr HJ, Berger G, Ritz JP, Holmer C. Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model. Invest New Drugs. 2012;30(3):927–935. doi:10.1007/s10637-011-9646-0
   PubMed Web of Science ®Google Scholar
• Pohlen U, Reszka R, Buhr HJ, Berger G. Hepatic arterial infusion in the treatment of liver metastases with PEG liposomes in combination with degradable starch microspheres (DSM) increases tumor 5-FU concentration. an animal study in CC-531 liver tumor-bearing rats. Anticancer Res. 2011;31(1):147–152.
   PubMed Web of Science ®Google Scholar
• Zhao C, Feng Q, Dou Z, et al. Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin. PLoS One. 2013;8(9):e73860. doi:10.1371/journal.pone.0073860
   PubMed Web of Science ®Google Scholar
• Li Y, Huang G, Diakur J, Wiebe LI. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv. 2008;5(4):299–302. doi:10.2174/156720108785915069
   PubMedGoogle Scholar
• Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 2001;221(1):159–166. doi:10.1148/radiol.2211001624
   PubMed Web of Science ®Google Scholar
• Widmann G, Schullian P, Haidu M, Bale R. Stereotactic radiofrequency ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance. Cardiovasc Intervent Radiol. 2012;35(3):570–580. doi:10.1007/s00270-011-0200-4
   PubMed Web of Science ®Google Scholar
• Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia. 2004;20(7):781–802. doi:10.1080/02656730410001711655
   PubMed Web of Science ®Google Scholar
• Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation. Chem Phys Lipids. 2012;165(4):424–437. doi:10.1016/j.chemphyslip.2011.12.002
   PubMed Web of Science ®Google Scholar
• Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60(24):6950–6957.
   PubMed Web of Science ®Google Scholar
• Gasselhuber A, Dreher MR, Negussie A, Wood BJ, Rattay F, Haemmerich D. Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int J Hyperthermia. 2010;26(5):499–513. doi:10.3109/02656731003623590
   PubMed Web of Science ®Google Scholar
• Tak WY, Lin SM, Wang Y, et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res. 2018;24(1):73–83. doi:10.1158/1078-0432.Ccr-16-2433
   PubMed Web of Science ®Google Scholar
• Mendes M, Sousa J, Pais A, Vitorino C. 4 - Clinical applications of nanostructured drug delivery systems: from basic research to translational medicine. In: Focarete ML, Tampieri A, editors. Core-Shell Nanostructures for Drug Delivery and Theranostics. Woodhead Publishing; 2018:43–116.
   Google Scholar
• Kumar A, Moralès O, Mordon S, Delhem N, Boleslawski E. Could photodynamic therapy be a promising therapeutic modality in hepatocellular carcinoma patients? A critical review of experimental and clinical studies. Cancers. 2021;13(20). doi:10.3390/cancers13205176
   Web of Science ®Google Scholar
• Menilli L, Milani C, Reddi E, Moret F. Overview of nanoparticle-based approaches for the combination of Photodynamic Therapy (PDT) and chemotherapy at the preclinical stage. Cancers. 2022;14(18):4462. doi:10.3390/cancers14184462
   PubMed Web of Science ®Google Scholar
• Ma S, Zhou J, Zhang Y, et al. An oxygen self-sufficient fluorinated nanoplatform for relieved tumor hypoxia and enhanced photodynamic therapy of cancers. ACS Appl Mater Interfaces. 2019;11(8):7731–7742. doi:10.1021/acsami.8b19840
   PubMed Web of Science ®Google Scholar
• Liang X, Chen M, Bhattarai P, Hameed S, Dai Z. Perfluorocarbon@porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer. ACS nano. 2020;14(10):13569–13583. doi:10.1021/acsnano.0c05617
   PubMed Web of Science ®Google Scholar
• Pan Y, He Y, Zhao X, et al. Engineered red blood cell membrane-coating salidroside/indocyanine green nanovesicles for high-efficiency hypoxic targeting phototherapy of triple-negative breast cancer. Adv Healthcare Mater. 2022;11(17):e2200962. doi:10.1002/adhm.202200962
   Web of Science ®Google Scholar
• Wilkinson AL, Qurashi M, Shetty S. The role of sinusoidal endothelial cells in the axis of inflammation and cancer within the liver. Front Physiol. 2020;11:990. doi:10.3389/fphys.2020.00990
   PubMed Web of Science ®Google Scholar
• Paunovska K, Da Silva Sanchez AJ, Sago CD, et al. Nanoparticles containing oxidized cholesterol deliver mRNA to the liver microenvironment at clinically relevant doses. Adv Mater. 2019;31(14):e1807748. doi:10.1002/adma.201807748
   PubMed Web of Science ®Google Scholar
• Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147–r1151. doi:10.1016/j.cub.2017.09.019
   PubMed Web of Science ®Google Scholar
• Benedicto A, Herrero A, Romayor I, et al. Liver sinusoidal endothelial cell ICAM-1 mediated tumor/endothelial crosstalk drives the development of liver metastasis by initiating inflammatory and angiogenic responses. Sci Rep. 2019;9(1):13111. doi:10.1038/s41598-019-49473-7
   PubMed Web of Science ®Google Scholar
• Aychek T, Miller K, Sagi-Assif O, et al. E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. Int J Cancer. 2008;123(8):1741–1750. doi:10.1002/ijc.23375
   PubMed Web of Science ®Google Scholar
• Zuo Y, Ren S, Wang M, et al. Novel roles of liver sinusoidal endothelial cell lectin in colon carcinoma cell adhesion, migration and in-vivo metastasis to the liver. Gut. 2013;62(8):1169–1178. doi:10.1136/gutjnl-2011-300593
   PubMed Web of Science ®Google Scholar
• Pattipeiluhu R, Arias-Alpizar G, Basha G, et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. Adv Mater. 2022;34(16):e2201095. doi:10.1002/adma.202201095
   PubMed Web of Science ®Google Scholar
• Campbell F, Bos FL, Sieber S, et al. Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake. ACS nano. 2018;12(3):2138–2150. doi:10.1021/acsnano.7b06995
   PubMed Web of Science ®Google Scholar
• Ukawa M, Fujiwara Y, Ando H, Shimizu T, Ishida T. Hepatic tumor metastases cause enhanced PEGylated liposome uptake by Kupffer cells. Biol Pharm Bull. 2016;39(2):215–220. doi:10.1248/bpb.b15-00611
   PubMed Web of Science ®Google Scholar
• van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res. 2002;12(1–2):81–94. doi:10.1081/lpr-120004780
   PubMed Web of Science ®Google Scholar
• Kruse J, von Bernstorff W, Evert K, et al. Macrophages promote tumour growth and liver metastasis in an orthotopic syngeneic mouse model of colon cancer. Int J Colorectal Dis. 2013;28(10):1337–1349. doi:10.1007/s00384-013-1703-z
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Amano H, Ito Y, et al. Angiotensin II subtype 1a receptor signaling in resident hepatic macrophages induces liver metastasis formation. Cancer Sci. 2017;108(9):1757–1768. doi:10.1111/cas.13306
   PubMed Web of Science ®Google Scholar
• Krug S, Abbassi R, Griesmann H, et al. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors. Int J Cancer. 2018;143(7):1806–1816. doi:10.1002/ijc.31562
   PubMed Web of Science ®Google Scholar
• Nielsen SR, Quaranta V, Linford A, et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat Cell Biol. 2016;18(5):549–560. doi:10.1038/ncb3340
   PubMed Web of Science ®Google Scholar
• Correia AL, Guimaraes JC, Auf der Maur P, et al. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature. 2021;594(7864):566–571. doi:10.1038/s41586-021-03614-z
   PubMed Web of Science ®Google Scholar
• Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11(5):1743–1750. doi:10.1158/1078-0432.Ccr-04-1195
   PubMed Web of Science ®Google Scholar
• Liu Z, Mo H, Liu R, et al. Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression. Cell Death Dis. 2021;12(12):1134. doi:10.1038/s41419-021-04418-9
   PubMed Web of Science ®Google Scholar
• Kaps L, Schuppan D. Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells. 2020;9(9):2027. doi:10.3390/cells9092027
   PubMed Web of Science ®Google Scholar
• Li Z, Wang F, Li Y, et al. Combined anti-hepatocellular carcinoma therapy inhibit drug-resistance and metastasis via targeting “substance P-hepatic stellate cells-hepatocellular carcinoma” axis. Biomaterials. 2021;276:121003. doi:10.1016/j.biomaterials.2021.121003
   PubMed Web of Science ®Google Scholar
• Li Y, Wu J, Lu Q, et al. GA&HA-modified liposomes for co-delivery of aprepitant and curcumin to inhibit drug-resistance and metastasis of hepatocellular carcinoma. Int J Nanomedicine. 2022;17:2559–2575. doi:10.2147/ijn.S366180
   PubMed Web of Science ®Google Scholar
• Qi C, Wang D, Gong X, et al. Co-delivery of curcumin and capsaicin by dual-targeting liposomes for inhibition of aHSC-induced drug resistance and metastasis. ACS Appl Mater Interfaces. 2021;13(14):16019–16035. doi:10.1021/acsami.0c23137
   PubMed Web of Science ®Google Scholar
• Guo J, Zeng H, Shi X, et al. A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial-mesenchymal transition reversion. J Nanobiotechnology. 2022;20(1):114. doi:10.1186/s12951-022-01311-1
   PubMed Web of Science ®Google Scholar
• Oshimi K, Kano S, Takaku F, Okumura K. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst. 1980;65(6):1265–1269.
   PubMedGoogle Scholar
• Uehara K, Ichida T, Sugahara S, et al. Systemic administration of liposome-encapsulated OK-432 prolongs the survival of rats with hepatocellular carcinoma through the induction of IFN-gamma-producing hepatic lymphocytes. J Gastroenterol Hepatol. 2002;17(1):81–90. doi:10.1046/j.1440-1746.2002.02675.x
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Chen C, Zhang S, Zhang R, et al. In situ tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor. Theranostics. 2020;10(26):11998–12010. doi:10.7150/thno.50806
   PubMed Web of Science ®Google Scholar
• Sharifi S, Caracciolo G, Mahmoudi M. Biomolecular corona affects controlled release of drug payloads from nanocarriers. Trends Pharmacol Sci. 2020;41(9):641–652. doi:10.1016/j.tips.2020.06.011
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163–173. doi:10.1016/j.molimm.2014.06.038
   PubMed Web of Science ®Google Scholar
• Rosales-Pérez KE, Elizalde-Velázquez GA, Gómez-Oliván LM, et al. Response to letter to the editor about Rosales-Pérez et al, 2022 (doi.org/10.1016/j.chemosphere.2022.133791) instigating reflections on methodological and analytical rigor in ecotoxicological studies based on the research by Rosales-Pérez et al. (2022) by Guilherme Malafaia. Chemosphere. 2023;312(Pt1):137128. doi:10.1016/j.chemosphere.2022.137128
   PubMedGoogle Scholar
• Turtoi A, Blomme A, Debois D, et al. Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology. 2014;59(3):924–934. doi:10.1002/hep.26608
   PubMed Web of Science ®Google Scholar
• Speciale A, Muscarà C, Molonia MS, Cristani M, Cimino F, Saija A. Recent advances in glycyrrhetinic acid-functionalized biomaterials for liver cancer-targeting therapy. Molecules. 2022;27(6):1775. doi:10.3390/molecules27061775
   PubMed Web of Science ®Google Scholar
• Sabbadin C, Bordin L, Donà G, Manso J, Avruscio G, Armanini D. Licorice: from pseudohyperaldosteronism to therapeutic uses. Front Endocrinol (Lausanne). 2019;10:484. doi:10.3389/fendo.2019.00484
   PubMed Web of Science ®Google Scholar
• Hasanzadeh A, Gholipour B, Rostamnia S, et al. Biosynthesis of AgNPs onto the urea-based periodic mesoporous organosilica (Ag(x)NPs/Ur-PMO) for antibacterial and cell viability assay. J Colloid Interface Sci. 2021;585:676–683. doi:10.1016/j.jcis.2020.10.047
   PubMed Web of Science ®Google Scholar
• Chodari L, Dilsiz Aytemir M, Vahedi P, et al. Targeting mitochondrial biogenesis with polyphenol compounds. Oxid Med Cell Longev. 2021;2021:4946711. doi:10.1155/2021/4946711
   PubMed Web of Science ®Google Scholar